Search

Your search keyword '"Chiriboga, Claudia A"' showing total 296 results

Search Constraints

Start Over You searched for: Author "Chiriboga, Claudia A" Remove constraint Author: "Chiriboga, Claudia A"
296 results on '"Chiriboga, Claudia A"'

Search Results

2. Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study

6. Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials.

7. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial

8. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial

9. Bulbar function in spinal muscular atrophy (SMA): State of art and new challenges. 21st July 2023, Rome, Italy

10. Delphi Consensus Panel on Assessing Clinically Meaningful Treatment Outcomes in Adults Living with Spinal Muscular Atrophy (SMA) (P2-11.007)

11. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial

12. Recruitment & retention program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA!

13. Natural history of infantile-onset spinal muscular atrophy.

14. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial

15. Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study.

16. Muscle-specific SMN reduction reveals motor neuron-independent disease in spinal muscular atrophy models

19. Recruitment & retention program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA!

21. JEWELFISH: 24-month Safety, Pharmacodynamic and Exploratory Efficacy Data in Non-Treatment-Naïve Patients with Spinal Muscular Atrophy (SMA) Receiving Treatment with Risdiplam (P7-9.004)

25. Newborn Screening for Spinal Muscular Atrophy in New York State

26. Quantitative Evaluation of Lower Extremity Joint Contractures in Spinal Muscular Atrophy: Implications for Motor Function

27. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy

29. Contributors

30. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy

31. Onasemnogene Abeparvovec for Presymptomatic Infants with Spinal Muscular Atrophy and Two Copies of SMN2 (S39.004)

32. Onasemnogene Abeparvovec in Presymptomatic Spinal Muscular Atrophy (SMA): SPR1NT Study Update in Children with Three Copies of SMN2 (P15-5.001)

33. JEWELFISH: Safety, Pharmacodynamic and Exploratory Efficacy Data in Non-Naïve Patients with Spinal Muscular Atrophy (SMA) Receiving Treatment with Risdiplam (P15-5.004)

34. Pooled Safety Data from the Risdiplam Clinical Trial Development Program (P18-5.001)

35. Bulbar function in spinal muscular atrophy (SMA): State of art and new challenges. 21st July 2023, Rome, Italy

36. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial

38. Psychometric properties of the PEDI-CAT for children and youth with spinal muscular atrophy

40. Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study

44. Onasemnogene Abeparvovec Gene Therapy in Presymptomatic Spinal Muscular Atrophy (SMA): SPR1NT Study Update in Children with 3 Copies of SMN2 (4163)

45. JEWELFISH: Safety and Pharmacodynamic Data in Non-Naïve Patients with Spinal Muscular Atrophy (SMA) Receiving Treatment with Risdiplam (2316)

46. Pooled Safety Data from the Risdiplam Clinical Trial Development Program (4184)

47. Onasemnogene Abeparvovec Gene Therapy in Presymptomatic Spinal Muscular Atrophy (SMA): SPR1NT Study Update in Children with 2 Copies of SMN2 (4190)

Catalog

Books, media, physical & digital resources